Antares Pharma (ATRS) 2.45 $ATRS
Antares Pharma: Preparing For An Inflection Point
Mark Chapman - at Seeking Alpha - Sat Feb 07, 8:32AM CST
TEVA: 56.77 (-0.58), ATRS: 2.45 (+0.05)
Seeking Alpha's Biotech Weekly: Intercept Pops, Provenge's Prince Valeant, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 30, 3:00PM CST
BCRX: 10.06 (-0.09), ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), PCYC: 163.28 (+0.23), ZSPH: 46.77 (+3.42), RMTI: 11.17 (+0.15), BCLI: 3.86 (-0.02), SIEN: 15.90 (+0.38), JNJ: 99.62 (+1.18), ECYT: 5.26 (-0.02), SNY: 49.42 (+0.82), LENS: 6.00 (-0.67), REGN: 402.40 (+0.66), SYK: 94.51 (+1.14), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), AMGN: 153.48 (+0.30), APPY: 0.45 (-0.01), MNKD: 7.00 (+0.02), CELG: 115.88 (+0.16), ISRG: 510.73 (+3.02), GILD: 101.90 (+1.10), ANIP: 62.69 (-0.43), MRK: 58.81 (-0.07), ALXN: 182.29 (+6.02), CCXI: 7.85 (+0.04), ICPT: 209.12 (+7.12), AEZS: 0.53 (unch), ATRS: 2.45 (+0.05), NASH: 31.48 (+0.01)
Global Needle-free Drug Delivery Technologies market 2015-2019: Key Vendors are 3M, Antares Pharma, Bioject Medical Technologies, Glide Pharmaceutical Technologies, PharmaJet and Zogenix
PR Newswire Europe - Wed Jan 28, 10:25AM CST
DUBLIN, Jan. 27, 2015 /PRNewswire/ --Research and Markets
ATRS: 2.45 (+0.05)
Intramuscular Drug Delivery Market & Pipeline Insight Report 2015
M2 - Wed Jan 28, 2:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/hg5jlj/intramuscular) has announced the addition of the "Intramuscular Drug Delivery Market & Pipeline Insight" report to their offering. Intramuscular drug delivery methods using molecular structures and polymers are expected to gain momentum in coming years. More structural, physical and biochemical improvements have to take place to increase their marketing potential. Underlying principles behind these materials are being discovered to increase their pharmacological benefits for future usage. Gels are another material required for future development better and efficient delivery of intramuscular drug to the patients. The capabilities of sustained release have been found to be associated with these materials which are expected to make sustainable market place in near future. Researchers are developing new materials with better biodegradability and sustained release capabilities for providing efficient intramuscular drug delivery. With the recent technological advances, it is expected that newer methods for intramuscular drug delivery will be developed and commercialized in coming years. Market size of these materials and methods is modest which is expected to steady growth but before doing so they have to improve a lot before becoming marketable. Many novel intramuscular drugs are at various phases of clinical trials which are expected to be available after some time. Pharmaceutical companies have already identified the opportunities involved in the development of intramuscular drugs and many of them are at advanced phases of clinical trials. They are supposed to be cost effective along with pharmacologically efficient and minimized side effects. Intramuscular Drug Delivery Market & Pipeline Insight Report Findings: - Intramuscular Drug Delivery Mechanism - Global Intramuscular Drug Delivery Market Outlook - Intramuscular Drug Pipeline by Company, Country, Indication & Phase - Intramuscular Drug Pipeline: 364 Drugs - Marketed Intramuscular Drugs: 186 Drugs - Majority Drugs in Phase-I Trials:108 - Global Intramuscular Drug Delivery Market Future Prospects Key Topics Covered: 1. Introduction to Intramuscular Drug Delivery 2. Overview of Different Drug Delivery Mechanisms 3. Intramuscular Drug Delivery Mechanism 4. Global Intramuscular Drug Delivery Market Outlook 5. Global Intramuscular Drug Delivery Market Dynamics 6. Intramuscular Drug Delivery Market Future Prospects 7. Intramuscular Drug Pipeline by Company, Country, Indication & Phase 8. Marketed Intramuscular Drugs by Company, Country & Indication 9. Discontinued & Suspended Intramuscular Drugs in Clinical Pipeline 10. Competitive Landscape - Antares Pharma - Eli Lily - Glaxo SmithKline - HMD pharmaceuticals - Inovio Pharmaceuticals - Merck - Novartis - Pacira Pharmaceuticals - Pfizer - Pharmajet - Teva Pharmaceutical For more information visit http://www.researchandmarkets.com/research/hg...ramuscular
INO: 6.80 (-0.15), MRK: 58.81 (-0.07), PCRX: 113.94 (-0.91), ATRS: 2.45 (+0.05), NVS: 102.20 (-0.17)
Antares not quite there on ANDA for sumatriptan
Seeking Alpha - at Seeking Alpha - Mon Jan 26, 7:33AM CST
TEVA: 56.77 (-0.58), ATRS: 2.45 (+0.05)
Antares Pharma Provides Regulatory Update on Sumatriptan Injection USP
Business Wire - Mon Jan 26, 6:00AM CST
Antares Pharma, Inc. (NASDAQ:ATRS) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the Abbreviated New Drug Application (ANDA) for Sumatriptan Injection USP for the acute treatment of migraine. The complete response letter from the FDA provided revisions to labelling and cited minor deficiencies. If approved, Sumatriptan Injection USP would represent the Company's first ANDA approval and second device approved from the VIBEX(R) auto injector platform. As previously disclosed, Teva Pharmaceutical Industries, Ltd. would distribute the product and share the profits equally with Antares Pharma.
ATRS: 2.45 (+0.05)
Will Patterson Companies' Safety Measures Hold? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 19, 3:50PM CST
Distributor of dental, veterinary, and rehabilitation supplies, Patterson Companies, Inc. (PDCO) has declared that it is taking necessary initiatives in order to prevent unsafe dental products from entering the market.
HYH: 44.50 (+0.52), BRLI: 34.63 (+0.06), PDCO: 50.65 (-0.16), ATRS: 2.45 (+0.05)
Global Needle-free Drug Delivery Technologies market 2015-2019 3M, Antares Pharma, Bioject Medical Technologies, Glide Pharmaceutical Technologies, PharmaJet & Zogenix Dominating
M2 - Thu Jan 15, 4:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/rt6m7j/global) has announced the addition of the "Global Needle-free Drug Delivery Technologies market 2015-2019" report to their offering. The Global Needle-free Drug Delivery Technologies market to grow at a CAGR of 13.5% over the period 2014-2019 This report covers the present scenario and the growth prospects of the Global Needle-free Drug Delivery Technologies market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various needle-free drug delivery systems with active mechanisms for skin permeation such as velocity, ultrasound, iontophoresis, thermo ablation, and electrophoresis. The introduction and enforcement of various laws mandating the use of safety needles/syringes and needle-free devices are one of the major trends in this market. With the introduction and enforcement of such laws, the Healthcare and Pharmaceuticals markets worldwide are now switching to the mandatory use of safety needles/syringes and needle-free devices to help protect those at risk of infection from NSIs and other unsafe injection practices. According to the report, increased safety and efficiency are the key factors responsible for the growth of the market. Needle-free drug delivery systems provide better acceptability, particularly in self-administration settings. Further, the report states that needle-free drug delivery systems are associated with increased technology because of which there is a decrease in the rate of adoption. These devices require training modules and instruction manuals for the users. This mode of drug delivery includes: - Jet Injectors - Transdermal Patches (Microneedles, Nanopatches) Key Vendors - 3M - Antares Pharma - Bioject Medical Technologies - Glide Pharmaceutical Technologies - PharmaJet - Zogenix For more information visit http://www.researchandmarkets.com/research/rt6m7j/global
ATRS: 2.45 (+0.05)
Premarket Gainers/Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Jan 13, 8:24AM CST
ANV: 0.97 (-0.03), ALX: 453.22 (-6.93), PCYC: 163.28 (+0.23), NLST: 1.86 (unch), ECOM: 9.69 (+0.63), VLCCF: 4.15 (-0.06), PHMD: 1.68 (+0.04), BNCL: 11.54 (-0.02), GURE: 1.64 (-0.04), CTIC: 2.23 (-0.02), AUY: 4.13 (+0.13), ATRS: 2.45 (+0.05)
Antares Pharma faces an extended Phase 3 QST study
Seeking Alpha - at Seeking Alpha - Tue Jan 13, 6:37AM CST
ATRS: 2.45 (+0.05)
Antares Pharma Announces Update to QuickShot(R) Testosterone Program
Business Wire - Tue Jan 13, 6:00AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that it has received written recommendations from the U.S. Food and Drug Administration (FDA) related to its clinical development program for QuickShot(R) Testosterone (QS T). The recommendations received were in response to various clinical, CMC (Chemistry, Manufacturing and Controls) and user study submissions made by the Company through November 2014. The Company believes that it has already factored many of the recommendations cited in the advice letter into the protocol of the ongoing phase 3 study and into the protocols for planned human use studies as a result of guidance provided by FDA at the May 2014 Type C meeting. Based on a single reported occurrence of hives in the Company's phase 2 study, which the FDA characterized as an apparent allergic reaction, as well as the known safety experience with other parenteral testosterone products, the FDA is recommending that the Company create a larger safety database, including approximately 350 subjects exposed to QS T with 200 subjects exposed for six months and 100 subjects exposed for a year. The Company does not believe that the adverse event of hives reported in the phase 2 study was related to study drug. Based on the number of subjects in previous studies and in the current phase 3 study, the Company anticipates that it may need approximately 70 additional subjects exposed to QS T for six months. The Company is assessing the FDA's comments in the advice letter and their impact on the timing of the filing of a New Drug Application for QS T with the FDA. The timing, cost and design of the study to obtain the additional 70 subjects and data required will be determined based on further discussion with the FDA. The Company continues to expect to release top-line pharmacokinetic data from the current phase 3 study in the second quarter of 2015.
ATRS: 2.45 (+0.05)
Henry Schein Expands Dental Line in North America, Stock Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 08, 1:30PM CST
Henry Schein's (HSIC) decision to distribute A-dec's products in North America reflects the former's commitment to expand its customers' access to the widest range of dental equipment.
HYH: 44.50 (+0.52), BRLI: 34.63 (+0.06), ATRS: 2.45 (+0.05), HSIC: 143.18 (+0.72)
Antares Pharma to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Business Wire - Thu Jan 08, 6:00AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Eamonn P. Hobbs, President and Chief Executive Officer, will present a corporate overview at the 33rd Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2015 at 9:00 a.m. Pacific Time.
JPM: 59.67 (+0.10), ATRS: 2.45 (+0.05)
Interesting ATRS Put Options For August 2015
at The Street - Wed Dec 24, 11:38AM CST
Investors in Antares Pharma Inc. saw new options become available this week, for the August 2015 expiration.
ATRS: 2.45 (+0.05)
Generic EpiPen Could Give These 2 Stocks A Jolt Of Adrenaline
Mark Chapman - at Seeking Alpha - Mon Dec 08, 3:48PM CST
PFE: 34.64 (-0.23), MYL: 55.85 (+1.34), TEVA: 56.77 (-0.58), ATRS: 2.45 (+0.05)
Antares Pharma to Present at the 25th Annual Oppenheimer Healthcare Conference
Business Wire - Wed Dec 03, 6:00AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Eamonn P. Hobbs, President and Chief Executive Officer, will present at the 25th Annual Oppenheimer Healthcare Conference on Wednesday, December 10, 2014 at 3:55 p.m. Eastern Time.
ATRS: 2.45 (+0.05)
Antares Pharma to Present at the 26th Annual Piper Jaffray Healthcare Conference
Business Wire - Tue Nov 25, 6:00AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Eamonn P. Hobbs, President and Chief Executive Officer, will present at the 26th Annual Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014 at 12:30 p.m. Eastern Time.
ATRS: 2.45 (+0.05)
Medac Pharma, Inc. Brings Motion to Preliminarily Prohibit Antares Sales of Otrexup to New Patients
PR Newswire - Mon Nov 24, 10:20AM CST
Medac Pharma, Inc., a privately held pharmaceutical company, today announced that it has filed a motion for a preliminary injunction against Antares Pharma, Inc. to prohibit sales of the 15, 20 and 25 mg doses of Otrexup(TM) (methotrexate) injection to new patients. The motion was filed in the United States District Court for the District of New Jersey in a suit for infringement of the U.S. patent 8,664,231 (the '231 patent). The patent, titled, "Concentrated Methotrexate Solutions," is directed to a method for the treatment of inflammatory autoimmune diseases by subcutaneously administrating methotrexate at a concentration of more than 30 mg/mL. Medac Pharma's Rasuvo(TM) (methotrexate injection) is available to fill the treatment needs of any patient affected by the requested injunction.
ATRS: 2.45 (+0.05)
Antares Pharma: Preparing For An Inflection Point
Mark Chapman - at Seeking Alpha - Sat Feb 07, 8:32AM CST
TEVA: 56.77 (-0.58), ATRS: 2.45 (+0.05)
Seeking Alpha's Biotech Weekly: Intercept Pops, Provenge's Prince Valeant, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 30, 3:00PM CST
BCRX: 10.06 (-0.09), ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), PCYC: 163.28 (+0.23), ZSPH: 46.77 (+3.42), RMTI: 11.17 (+0.15), BCLI: 3.86 (-0.02), SIEN: 15.90 (+0.38), JNJ: 99.62 (+1.18), ECYT: 5.26 (-0.02), SNY: 49.42 (+0.82), LENS: 6.00 (-0.67), REGN: 402.40 (+0.66), SYK: 94.51 (+1.14), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), AMGN: 153.48 (+0.30), APPY: 0.45 (-0.01), MNKD: 7.00 (+0.02), CELG: 115.88 (+0.16), ISRG: 510.73 (+3.02), GILD: 101.90 (+1.10), ANIP: 62.69 (-0.43), MRK: 58.81 (-0.07), ALXN: 182.29 (+6.02), CCXI: 7.85 (+0.04), ICPT: 209.12 (+7.12), AEZS: 0.53 (unch), ATRS: 2.45 (+0.05), NASH: 31.48 (+0.01)
Global Needle-free Drug Delivery Technologies market 2015-2019: Key Vendors are 3M, Antares Pharma, Bioject Medical Technologies, Glide Pharmaceutical Technologies, PharmaJet and Zogenix
PR Newswire Europe - Wed Jan 28, 10:25AM CST
DUBLIN, Jan. 27, 2015 /PRNewswire/ --Research and Markets
ATRS: 2.45 (+0.05)
Intramuscular Drug Delivery Market & Pipeline Insight Report 2015
M2 - Wed Jan 28, 2:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/hg5jlj/intramuscular) has announced the addition of the "Intramuscular Drug Delivery Market & Pipeline Insight" report to their offering. Intramuscular drug delivery methods using molecular structures and polymers are expected to gain momentum in coming years. More structural, physical and biochemical improvements have to take place to increase their marketing potential. Underlying principles behind these materials are being discovered to increase their pharmacological benefits for future usage. Gels are another material required for future development better and efficient delivery of intramuscular drug to the patients. The capabilities of sustained release have been found to be associated with these materials which are expected to make sustainable market place in near future. Researchers are developing new materials with better biodegradability and sustained release capabilities for providing efficient intramuscular drug delivery. With the recent technological advances, it is expected that newer methods for intramuscular drug delivery will be developed and commercialized in coming years. Market size of these materials and methods is modest which is expected to steady growth but before doing so they have to improve a lot before becoming marketable. Many novel intramuscular drugs are at various phases of clinical trials which are expected to be available after some time. Pharmaceutical companies have already identified the opportunities involved in the development of intramuscular drugs and many of them are at advanced phases of clinical trials. They are supposed to be cost effective along with pharmacologically efficient and minimized side effects. Intramuscular Drug Delivery Market & Pipeline Insight Report Findings: - Intramuscular Drug Delivery Mechanism - Global Intramuscular Drug Delivery Market Outlook - Intramuscular Drug Pipeline by Company, Country, Indication & Phase - Intramuscular Drug Pipeline: 364 Drugs - Marketed Intramuscular Drugs: 186 Drugs - Majority Drugs in Phase-I Trials:108 - Global Intramuscular Drug Delivery Market Future Prospects Key Topics Covered: 1. Introduction to Intramuscular Drug Delivery 2. Overview of Different Drug Delivery Mechanisms 3. Intramuscular Drug Delivery Mechanism 4. Global Intramuscular Drug Delivery Market Outlook 5. Global Intramuscular Drug Delivery Market Dynamics 6. Intramuscular Drug Delivery Market Future Prospects 7. Intramuscular Drug Pipeline by Company, Country, Indication & Phase 8. Marketed Intramuscular Drugs by Company, Country & Indication 9. Discontinued & Suspended Intramuscular Drugs in Clinical Pipeline 10. Competitive Landscape - Antares Pharma - Eli Lily - Glaxo SmithKline - HMD pharmaceuticals - Inovio Pharmaceuticals - Merck - Novartis - Pacira Pharmaceuticals - Pfizer - Pharmajet - Teva Pharmaceutical For more information visit http://www.researchandmarkets.com/research/hg...ramuscular
INO: 6.80 (-0.15), MRK: 58.81 (-0.07), PCRX: 113.94 (-0.91), ATRS: 2.45 (+0.05), NVS: 102.20 (-0.17)
Antares not quite there on ANDA for sumatriptan
Seeking Alpha - at Seeking Alpha - Mon Jan 26, 7:33AM CST
TEVA: 56.77 (-0.58), ATRS: 2.45 (+0.05)
Antares Pharma Provides Regulatory Update on Sumatriptan Injection USP
Business Wire - Mon Jan 26, 6:00AM CST
Antares Pharma, Inc. (NASDAQ:ATRS) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the Abbreviated New Drug Application (ANDA) for Sumatriptan Injection USP for the acute treatment of migraine. The complete response letter from the FDA provided revisions to labelling and cited minor deficiencies. If approved, Sumatriptan Injection USP would represent the Company's first ANDA approval and second device approved from the VIBEX(R) auto injector platform. As previously disclosed, Teva Pharmaceutical Industries, Ltd. would distribute the product and share the profits equally with Antares Pharma.
ATRS: 2.45 (+0.05)
Will Patterson Companies' Safety Measures Hold? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 19, 3:50PM CST
Distributor of dental, veterinary, and rehabilitation supplies, Patterson Companies, Inc. (PDCO) has declared that it is taking necessary initiatives in order to prevent unsafe dental products from entering the market.
HYH: 44.50 (+0.52), BRLI: 34.63 (+0.06), PDCO: 50.65 (-0.16), ATRS: 2.45 (+0.05)
Global Needle-free Drug Delivery Technologies market 2015-2019 3M, Antares Pharma, Bioject Medical Technologies, Glide Pharmaceutical Technologies, PharmaJet & Zogenix Dominating
M2 - Thu Jan 15, 4:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/rt6m7j/global) has announced the addition of the "Global Needle-free Drug Delivery Technologies market 2015-2019" report to their offering. The Global Needle-free Drug Delivery Technologies market to grow at a CAGR of 13.5% over the period 2014-2019 This report covers the present scenario and the growth prospects of the Global Needle-free Drug Delivery Technologies market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various needle-free drug delivery systems with active mechanisms for skin permeation such as velocity, ultrasound, iontophoresis, thermo ablation, and electrophoresis. The introduction and enforcement of various laws mandating the use of safety needles/syringes and needle-free devices are one of the major trends in this market. With the introduction and enforcement of such laws, the Healthcare and Pharmaceuticals markets worldwide are now switching to the mandatory use of safety needles/syringes and needle-free devices to help protect those at risk of infection from NSIs and other unsafe injection practices. According to the report, increased safety and efficiency are the key factors responsible for the growth of the market. Needle-free drug delivery systems provide better acceptability, particularly in self-administration settings. Further, the report states that needle-free drug delivery systems are associated with increased technology because of which there is a decrease in the rate of adoption. These devices require training modules and instruction manuals for the users. This mode of drug delivery includes: - Jet Injectors - Transdermal Patches (Microneedles, Nanopatches) Key Vendors - 3M - Antares Pharma - Bioject Medical Technologies - Glide Pharmaceutical Technologies - PharmaJet - Zogenix For more information visit http://www.researchandmarkets.com/research/rt6m7j/global
ATRS: 2.45 (+0.05)
Premarket Gainers/Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Jan 13, 8:24AM CST
ANV: 0.97 (-0.03), ALX: 453.22 (-6.93), PCYC: 163.28 (+0.23), NLST: 1.86 (unch), ECOM: 9.69 (+0.63), VLCCF: 4.15 (-0.06), PHMD: 1.68 (+0.04), BNCL: 11.54 (-0.02), GURE: 1.64 (-0.04), CTIC: 2.23 (-0.02), AUY: 4.13 (+0.13), ATRS: 2.45 (+0.05)
Antares Pharma faces an extended Phase 3 QST study
Seeking Alpha - at Seeking Alpha - Tue Jan 13, 6:37AM CST
ATRS: 2.45 (+0.05)
Antares Pharma Announces Update to QuickShot(R) Testosterone Program
Business Wire - Tue Jan 13, 6:00AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that it has received written recommendations from the U.S. Food and Drug Administration (FDA) related to its clinical development program for QuickShot(R) Testosterone (QS T). The recommendations received were in response to various clinical, CMC (Chemistry, Manufacturing and Controls) and user study submissions made by the Company through November 2014. The Company believes that it has already factored many of the recommendations cited in the advice letter into the protocol of the ongoing phase 3 study and into the protocols for planned human use studies as a result of guidance provided by FDA at the May 2014 Type C meeting. Based on a single reported occurrence of hives in the Company's phase 2 study, which the FDA characterized as an apparent allergic reaction, as well as the known safety experience with other parenteral testosterone products, the FDA is recommending that the Company create a larger safety database, including approximately 350 subjects exposed to QS T with 200 subjects exposed for six months and 100 subjects exposed for a year. The Company does not believe that the adverse event of hives reported in the phase 2 study was related to study drug. Based on the number of subjects in previous studies and in the current phase 3 study, the Company anticipates that it may need approximately 70 additional subjects exposed to QS T for six months. The Company is assessing the FDA's comments in the advice letter and their impact on the timing of the filing of a New Drug Application for QS T with the FDA. The timing, cost and design of the study to obtain the additional 70 subjects and data required will be determined based on further discussion with the FDA. The Company continues to expect to release top-line pharmacokinetic data from the current phase 3 study in the second quarter of 2015.
ATRS: 2.45 (+0.05)
Henry Schein Expands Dental Line in North America, Stock Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 08, 1:30PM CST
Henry Schein's (HSIC) decision to distribute A-dec's products in North America reflects the former's commitment to expand its customers' access to the widest range of dental equipment.
HYH: 44.50 (+0.52), BRLI: 34.63 (+0.06), ATRS: 2.45 (+0.05), HSIC: 143.18 (+0.72)
Antares Pharma to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Business Wire - Thu Jan 08, 6:00AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Eamonn P. Hobbs, President and Chief Executive Officer, will present a corporate overview at the 33rd Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2015 at 9:00 a.m. Pacific Time.
JPM: 59.67 (+0.10), ATRS: 2.45 (+0.05)
Interesting ATRS Put Options For August 2015
at The Street - Wed Dec 24, 11:38AM CST
Investors in Antares Pharma Inc. saw new options become available this week, for the August 2015 expiration.
ATRS: 2.45 (+0.05)
Generic EpiPen Could Give These 2 Stocks A Jolt Of Adrenaline
Mark Chapman - at Seeking Alpha - Mon Dec 08, 3:48PM CST
PFE: 34.64 (-0.23), MYL: 55.85 (+1.34), TEVA: 56.77 (-0.58), ATRS: 2.45 (+0.05)
Antares Pharma to Present at the 25th Annual Oppenheimer Healthcare Conference
Business Wire - Wed Dec 03, 6:00AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Eamonn P. Hobbs, President and Chief Executive Officer, will present at the 25th Annual Oppenheimer Healthcare Conference on Wednesday, December 10, 2014 at 3:55 p.m. Eastern Time.
ATRS: 2.45 (+0.05)
Antares Pharma to Present at the 26th Annual Piper Jaffray Healthcare Conference
Business Wire - Tue Nov 25, 6:00AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Eamonn P. Hobbs, President and Chief Executive Officer, will present at the 26th Annual Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014 at 12:30 p.m. Eastern Time.
ATRS: 2.45 (+0.05)
Medac Pharma, Inc. Brings Motion to Preliminarily Prohibit Antares Sales of Otrexup to New Patients
PR Newswire - Mon Nov 24, 10:20AM CST
Medac Pharma, Inc., a privately held pharmaceutical company, today announced that it has filed a motion for a preliminary injunction against Antares Pharma, Inc. to prohibit sales of the 15, 20 and 25 mg doses of Otrexup(TM) (methotrexate) injection to new patients. The motion was filed in the United States District Court for the District of New Jersey in a suit for infringement of the U.S. patent 8,664,231 (the '231 patent). The patent, titled, "Concentrated Methotrexate Solutions," is directed to a method for the treatment of inflammatory autoimmune diseases by subcutaneously administrating methotrexate at a concentration of more than 30 mg/mL. Medac Pharma's Rasuvo(TM) (methotrexate injection) is available to fill the treatment needs of any patient affected by the requested injunction.
ATRS: 2.45 (+0.05)
